Overview

Full Product Details

Author:   Daniel Wisehart
Publisher:   Taylor & Francis Ltd
Imprint:   Routledge
Weight:   0.453kg
ISBN:  

9780367584993

ISBN 10:   0367584999
Pages:   232
Publication Date:   30 June 2020
Audience:   College/higher education ,  Professional and scholarly ,  Postgraduate, Research & Scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Acknowledgments List of abbreviations 1 Introduction 1.1 International drug control after UNGASS 2016: more of the same or towards a fundamental turning point? 1.2 Objectives and methodology of this book 2 The sources and actors of the international drug control system 2.1 The primary sources of the international drug control system 2.2 The institutions of the international drug control system and a typology of their secondary instruments 2.3 Conclusion 3 The emergence of the international drug control system 3.1 Towards one coherent obligation to confine drugs to medical and scientific purposes 3.2 A constant expansion of the international drug control system 3.3 The international drug control system as a prime example of the law of cooperation 3.4 Conclusion 4 The objective of the international drug control system: limitation of drugs to medical and scientific purposes 4.1 The need to understand the limitation of drugs to medical and scientific purposes 4.2 The meaning of the limitation of all drug-related activities to medical and scientific purposes 4.3 Exceptions to the limitation of drugs to medical and scientific purposes within the international drug control system 4.4 Options to deviate from the limitation of drugs to medical and scientific purposes in the international drug control system 4.5 Does international human rights law conflict with the limitation of drugs to medical and scientific purposes? 4.6 Conclusion 5 The material scope of the international drug control system 5.1 Substances limited to medical and scientific purposes 5.2 Modification of the scope of application of the international drug control system (scheduling) 5.3 Prospects for exempting cannabis and the coca leaf from drug control’s scope of application 5.4 The challenge of regulating uncertainty: the rise of new psychoactive substances and the international drug control system 5.5 Conclusion 6 Challenges to the implementation of the international drug control system 6.1 Control of the licit supply chain: achieving a balance between limiting and ensuring an adequate availability of drug supply? 6.2 Suppression of illicit supply: the UN Drug Conventions as a punitive and sanction-oriented system of control? 6.3 Demand-reduction obligations providing for a human- and health-oriented treatment of drug users? 6.4 Fairness and the premise of the international drug control system to limit drugs to medical and scientific purposes by relying on a control of drug supply 6.5 Conclusion 7 Concluding remarks and outlook Bibliography Index

Reviews

Author Information

Daniel Wisehart is an associate at Wach + Meckes LLP, Munich. He has previously worked as a researcher at the Universität Potsdam and the Universität Freiburg and clerked for the European Court of Human Rights.

Tab Content 6

Author Website:  

Countries Available

All regions